General MedicationsINTRAMUSCULARStandard

ERZOFRI

PALIPERIDONE PALMITATE

Standard Dose

39MG/0.25ML (39MG/0.25ML)

Max Dose

Refer to approved labeling

Primary Use

Review priority: STANDARD Marketing status: Prescription

Summary

Approval overview ERZOFRI is listed in Drugs@FDA under application 216352 (NDA).

Review priority: STANDARD Marketing status: Prescription Active ingredient PALIPERIDONE PALMITATE Form and strength SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR - 39MG/0.25ML (39MG/0.25ML) Sponsor LUYE INNOMIND PHARMA Submission history Latest submission status date: 2025-01-22 00:00:00.

Structured Monograph

Clinical summary

Approval overview ERZOFRI is listed in Drugs@FDA under application 216352 (NDA). Review priority: STANDARD Marketing status: Prescription Active ingredient PALIPERIDONE PALMITATE Form and strength SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR - 39MG/0.25ML (39MG/0.25ML) Sponsor LUYE INNOMIND PHARMA Submission history Latest submission status date: 2025-01-22 00:00:00. Submission type: SUPPL.

Monitoring

• Marketing status: Prescription
• Review priority: STANDARD

Interaction Notes

No interaction notes stored yet.